Huateng Pharma Develops Spray Against New Coronavirus Infection

This year is an unusual year due to the infection of the Novel Coronavirus Pneumonia (NCP) epidemic. Hunan Huateng Pharmaceutical Co., Ltd. (hereinafter referred to as Huateng)， as a drug research and development company with rich experience in developing antiviral drugs, has attached close attention to this matter. Considering that there is no targeted medicine for novel coronavirus pneumonia (NCP) infection and that NCP virus is highly similar to SARS / Middle East Respiratory Syndrome (MERS) virus, Huateng aims to use old drugs to develop new indications and Immediately decided to urgently set up an emergency project tackling team led by Deng Zeping, Chairman of Huateng Pharmaceuticals, National Ten Thousand Plan Expert, Wu Siqing, Dean of Huateng Pharmaceutical College and former senior fellow of the United States Pharmacopeia.